Can you provide the upcoming earnings date for Taiwan Liposome Company Ltd ADR?
Taiwan Liposome Company Ltd ADR (TLC) will report earnings on 2022-01-11.
Taiwan Liposome Company Ltd ADR (TLC) Forecast, Price Target & Analyst Ratings
NASDAQ:TLC
Current stock price
7
0 (0%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Taiwan Liposome Company Ltd ADR (TLC).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.00
Upside
-100.00%
From current price of $7.00 to mean target of $0.00, Based on 2 analyst forecasts
Low
$0.00
Median
$0.00
High
$0.00
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
TLC was analyzed by 2 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about TLC.
In the previous month the buy percentage consensus was at a similar level.
Only 2 analysts analyzed TLC. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-07-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Jan 11, 2022
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 246.21% | N/A -40.89% | N/A -35.08% | N/A 54.77% | N/A 8.22% | N/A 9.85% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A 28.66% | N/A -7.69% | N/A 4.76% | N/A -15.56% | N/A 6.33% | N/A |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1.02%
EPS Next 5 Year
-0.76%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
2.83%
Revenue Next 5 Year
4.54%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Taiwan Liposome Company Ltd ADR / TLC Forecast FAQ
Can you provide the expected long term growth rate for Taiwan Liposome Company Ltd ADR stock?
The expected long term growth rate for Taiwan Liposome Company Ltd ADR (TLC) is 2.83%.